Liraglutide Explored as Novel Treatment for Nicotine Dependence and Weight Management

Nicotine dependence, commonly known as smoking addiction, remains a leading cause of preventable illness and death worldwide, often complicated by weight gain after quitting. Current pharmacotherapies have varying success rates and side effects. Glucagon-like Peptide-1 (GLP-1) receptor agonists, like Liraglutide, are approved for type 2 diabetes and chronic weight management, and emerging research suggests they may also influence reward pathways in the brain. This study investigates if Liraglutide can serve as a novel pharmacotherapy to aid both smoking cessation and mitigate post-cessation weight gain.

While specific quantitative results from this completed Phase 2 trial are not detailed in the provided record, the study was designed to evaluate the efficacy of Liraglutide in reducing nicotine dependence and promoting weight loss. The 40 participants were monitored for changes in smoking behavior and body weight. The trial aimed to provide data on how Liraglutide compares to placebo in these critical areas, building on the known effects of GLP-1 receptor agonists on reward pathways and metabolism. Data collection included metrics such as daily cigarette consumption, quit attempts, and body mass index changes. The primary objective was to determine if daily Liraglutide 3.0 mg could significantly impact smoking cessation rates and lead to clinically meaningful weight reduction in adults with excess weight (BMI ≥27) or obesity (BMI ≥30).